China
Africa
Explore chapters and articles related to this topic
Drugs Affecting the Musculoskeletal System
Published in Radhwan Nidal Al-Zidan, Drugs in Pregnancy, 2020
Risk Summary: It is better to be avoided during the 1st and 3rd Trimesters because the pregnancy experience in humans suggests a risk of pulmonary hypertension of the newborn, SABs, and congenital malformations linked to the use of Meloxicam.
The Consultation Expertise Model
Published in Peter Worrall, Adrian French, Les Ashton, Justin Allen, Advanced Consulting In Family Medicine, 2018
Peter Worrall, Adrian French, Les Ashton
Doctor 1 takes a careful history, including the medication, and establishes that the meloxicam is only partially helpful and that the patient doesn’t like taking tablets. She asks whether she can have an injection. The doctor checks his understanding: ‘Did you know anyone that had injections?’ and then asks after the patient has responded in the affirmative ‘After injections, how long did it last for?’ The patient replies, I think it actually resolved the situation.
Clinical pharmacology and therapeutics: nonopioids
Published in Nigel Sykes, Michael I Bennett, Chun-Su Yuan, Clinical Pain Management, 2008
This explains the increased thrombotic risk of COX-2 inhibitors. It is less clear why many nonselective NSAIDs also carry a thrombotic risk. Relatively high COX-2 selectivity could explain the prothrombotic tendency of diclofenac but not that of indometacin. Meloxicam carries a moderately elevated risk;262, 263 [III] if due to predominant COX-2 inhibition this should reduce with higher doses, as COX-1 inhibition becomes more relevant. Celecoxib, whose in vitro COX-2 selectivity is roughly in line with diclofenac, may undermine this hypothesis (but see below under Individual NSAIDs). It is entirely plausible, of course, that non-COX mechanisms might contribute with individual drugs. Indeed, experimental data suggest that at least some of the thrombotic activity of rofecoxib may be independent of the active cyclooxygenase site.23
Early perioperative versus postoperative meloxicam for pain control in patients undergoing orthopedic surgery: a systematic review and Meta-analysis of randomized controlled trials
Published in Current Medical Research and Opinion, 2023
Abdelrahman Mahmoud, Mohamed Abuelazm, Ali Ashraf Salah Ahmed, Mahmoud Elshinawy, Toka Ashour, Mohamed Abugdida, Basel Abdelazeem
Meloxicam is an NSAID that is often used to treat musculoskeletal disorders by inhibiting prostaglandin synthesis and alleviating the inflammatory process. Meloxicam has been widely used to treat musculoskeletal inflammatory disorders, including osteoarthritis and rheumatoid arthritis6. Multiple trials showed that pre-and postoperative administration of meloxicam decreases postoperative pain in dental procedures and total abdominal hysterectomy which can support the clinical applicability of meloxicam for perioperative pain management7–9. Moreover, a previously published meta-analysis favored preventive administration of acetaminophen over post-incisional acetaminophen administration for pain control and opioid consumption reduction after various surgeries10.
Combination anesthetic therapy: co-delivery of ropivacaine and meloxicam using transcriptional transactivator peptide modified nanostructured lipid carriers in vitro and in vivo
Published in Drug Delivery, 2022
Shu Yuan, Jun Chen, Shuo Feng, Min Li, Yingui Sun, Yuzhen Liu
In vivo anesthetic pain relief effects were assessed in rats whose left hind paw were injured. Meloxicam is a long-acting NSAID, which can alleviate pain and reduce inflammation at the injured area (Samad et al., 2001). Since MLX has anti-inflammatory activities, it may be useful in reducing the resulting pain behaviors in the prepared rats (Khalil et al., 2014). In the present research, TAT-NLCs-RVC/MLX showed better anesthetic pain relief ability than that of single RVC loaded TAT-NLCs-RVC, which could prove the reduction effect of MLX that enhanced the efficiency of the whole system. These results illustrated the anesthetic pain relief ability of the present constructed system was significantly improved by the TAT modification through the enhanced skin permeation efficiency and the co-delivery of MLX along with RVC that improved pain management by reducing inflammation at the injured area. TAT-NLCs-RVC/MLX could be used as a promising system to achieve synergistic analgesic effect.
Long-term radial extracorporeal shock wave therapy for neurogenic heterotopic ossification after spinal cord injury: A case report
Published in The Journal of Spinal Cord Medicine, 2022
Yun Li, Yulan Zhu, Zhen Xie, Congyu Jiang, Fang Li
A 30-year-old woman with no notable past medical history suffered from a car accident presented with weakness of extremities without loss of motion (LOM) and severe pain in Sep 25th, 2017. Immediate cervical MRI showed the vertebral compression fracture in C6 along with an abnormal signal in the spinal cord at the according level. The patient received an emergent surgery of C6 decompression, debridement, bone grafting and internal fixation under general anesthesia. After the surgery, her condition was steady and routine physical therapies were followed for pain release and motor function recovery. One month later, she had a bulging area with swelling and pain in her left hip, particularly in the lateral aspect, restricting the hip motion. The radiographic exam suggested there was ossifying myositis in the left hip. Mild joint mobilization therapy was then adopted to relieve pain and maintain ROM of the left hip. However, she complained of severe pain and LOM later. The bulging area had been gradually enlarged, and an ossification mass was found in the left hip joint. Several months later, radiographic exam suggested that the ossification mass was in the proximal end of the left femur. The patient was then diagnosed with NHO and referred to our department for further rehabilitation in January 2018. In order to relieve the inflammation, meloxicam was prescribed for four months. After the treatment, the patient reported that her pain had been slightly eased, however, there was no radiographic change in the size of the ossification mass pre- and post-treatment.